Tuberculosis Clinical Trial
— HCD CoPOfficial title:
Human-centered Design and Communities of Practice to Improve Delivery of Home-based Tuberculosis Contact Investigation in Uganda
Verified date | February 2024 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In a previous randomized control trial, the investigators identified gaps in the implementation of tuberculosis (TB) contact investigation at multiple levels of the service delivery cascade. Drawing on prior experiences, the investigators have recently developed a novel strategy to enhance the implementation of routine contact investigation procedures. This user-centered implementation strategy was created through serial prototyping guided by human-centered design (HCD) and employs communities of practice (CoP) as an adjunctive adaptation and sustainment strategy. The investigators are now conducting a stepped-wedge, cluster-randomized implementation trial in 12 study sites in Uganda to determine if the resulting user-centered implementation strategy enhances the delivery of TB contact investigation and other implementation outcomes, and also improves health outcomes.
Status | Completed |
Enrollment | 10477 |
Est. completion date | October 26, 2023 |
Est. primary completion date | October 26, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Health centre inclusion criteria: 1. Reporting =12 index TB cases per month to the national TB program, 2. Located outside the borders of but =180 km from Kampala District Health centre exclusion criteria: 1) Administrators of the health centre do not agree to participate in the study Individual inclusion criteria for index persons with TB (also known as index TB patients or TB cases): 1. Being an adult or child recorded as a new TB case in the on-site National TB and Leprosy Programme TB treatment register, and 2. Residing =40 km from the enrolling health centre, Individual exclusion criteria for index persons with TB : 1. Lacking the capacity to consent to contact investigation, 2. Lacking close contacts, 3. Having possible or confirmed drug-resistant TB, 4. Previously received TB contact investigation within the last 2 months, and 5. Not agreeing to refer close contacts for contact investigation. Inclusion criteria for close contacts: 1) Being an adult or child reporting =12 cumulative hours with the TB patient inside an enclosed space within the previous 3 months, Exclusion criteria for close contacts: 1. Lacking the capacity to consent to contact investigation, 2. Currently taking treatment for active TB, and 3. Not agreeing to participate in contact investigation. |
Country | Name | City | State |
---|---|---|---|
Uganda | Uganda Tuberculosis Implementation Research Consortium | Kampala |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Heart, Lung, and Blood Institute (NHLBI), National Institute of Allergy and Infectious Diseases (NIAID) |
Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Completion of TB Evaluation | The difference in proportions of close contacts who are experiencing TB symptoms who complete TB evaluation within 60 days of the TB patient's treatment initiation date | 60 days | |
Secondary | TB Yield (symptomatic contacts) | The difference between study periods in proportions of contacts diagnosed with active TB and initiated on treatment within 60 days of the TB patient's treatment initiation | 60 days | |
Secondary | Initiation of TB Preventative Therapy | The difference between study periods in proportions of contacts initiating TB preventative therapy (TPT) within 60 days of the TB patient's treatment initiation | 60 days | |
Secondary | Number of contacts diagnosed with active TB | The difference between study periods in counts of the number of contacts diagnosed with active TB | 60 days | |
Secondary | Number of contacts initiating TB Preventative Therapy | The difference between study periods in counts of the number of contacts initiating TPT | 60 days | |
Secondary | TB Yield (all contacts) | The difference between study periods in proportions of all TB cases among contacts | 60 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |